ArticlePloS one2025
Global burden of head and neck cancer from 1990 to 2021: A comprehensive analysis and projections to 2030 based on the global burden of disease study 2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guidelines for nutrition in adults with head and neck cancer: The American Society for Parenteral and Enteral Nutrition.JPEN. Journal of parenteral and enteral nutrition · 2026Guideline
- Digital Twins for Targeted Therapy in Head and Neck Cancer: From Molecular Stratification to Resistance-Aware Combination Strategies.Current oncology (Toronto, Ont.) · 2026Review
- A Qualitative Study of Patient and Caregiver Perspectives on Locally Advanced Head and Neck Cancer in the United States.Oncology and therapy · 2026Article
- Article
- Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.Current oncology reports · 2026Review
- Imaging findings in the temporomandibular joint complex following radiation therapy for head and neck cancer: a review.Insights into imaging · 2026Review
- Automated Pretreatment Thoracic CT-Based Body Composition Analysis Predicts Progression-Free Survival in Head and Neck Cancer.Journal of clinical medicine · 2026Article
- Clinically relevant radiation therapy doses and obturation techniques modulate the adhesive performance of a resin-based sealer: interfacial integrity and bond strength analyses.Clinical oral investigations · 2026Article
- Overall survival and prognostic factors of oral cavity and oropharyngeal squamous cell carcinomas in Saudi Arabia: a population-based cohort study (2000-2019).Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck cancer (HNC) is a significant global health concern with rising incidence and mortality in certain regions. This study aimed to evaluate the global burden and temporal trends of HNC from 1990 to 2021 and to project its future burden through 2030.
methodsData were obtained from the Global Burden of Disease (GBD) 2021 study. Joinpoint regression was used to assess temporal trends in age-standardized incidence rates (ASIR), age-standardized death rates (ASDR), and disability-adjusted life years (DALYs). Age-period-cohort (APC) and Bayesian APC (BAPC) models were applied to evaluate age, period, and cohort effects and to project future trends. Decomposition analysis was conducted to explore the contributions of population aging, growth, and epidemiological changes.
resultsIn 2021, there were 792,280 new HNC cases and 424,066 deaths globally. Age-standardized incidence rates remained stable, while death rates and DALYs significantly declined. Incidence rose notably in East Asia, whereas mortality and DALYs increased substantially in Oceania. Gender differences were evident, with higher burdens in males, although female incidence rates recently increased. Aging and population growth were key contributors to the rising burden. Projections suggest a notable increase in female incidence and continued decline in male DALYs by 2030. Among HNC subtypes, lip and oral cavity cancers had the highest burden, whereas other pharyngeal cancers showed increasing incidence trends.
conclusionsDespite overall declines in mortality and disease burden, the global incidence of HNC remains substantial. Targeted interventions-such as tobacco and alcohol control and widespread HPV vaccination-are essential to mitigate the future burden of HNC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.